Show simple item record

dc.contributor.authorMeiring, James Een
dc.contributor.authorGibani, Malicken
dc.contributor.authorTyVAC Consortium Meeting Group:,en
dc.date.accessioned2019-02-16T00:30:37Z
dc.date.available2019-02-16T00:30:37Z
dc.date.issued2017-09en
dc.identifier.issn0264-410X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/289490
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectTyVAC Consortium Meeting Group:en
dc.subjectHumansen
dc.subjectTyphoid Feveren
dc.subjectTyphoid-Paratyphoid Vaccinesen
dc.subjectVaccines, Conjugateen
dc.subjectClinical Trials as Topicen
dc.subjectCongresses as Topicen
dc.titleThe Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26-27 October 2016, Oxford, UK.en
dc.typeArticle
prism.endingPage5088
prism.issueIdentifier38en
prism.publicationDate2017en
prism.publicationNameVaccineen
prism.startingPage5081
prism.volume35en
dc.identifier.doi10.17863/CAM.36740
dcterms.dateAccepted2017-08-01en
rioxxterms.versionofrecord10.1016/j.vaccine.2017.08.001en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2017-09en
dc.contributor.orcidGibani, Malick [0000-0003-1781-0053]
dc.identifier.eissn1873-2518
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idBill & Melinda Gates Foundation (via University of Oxford) (R46783/CN002 HNR00651)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International